Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Flecainide/modafinil (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Theranexus
- 25 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2019 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020.
- 09 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.